新华财经上海1月15日电（记者杨溢仁）2026年以来，转债市场延续了2025年末的高位运行态势。就市 场联动看，转债表现与A股的强势走势深度绑定，年初上证指数突破4000点带动风险偏好提升，可转债 基金成为了债基中的"亮色"，截至1月7日，其年内的平均涨幅超3.6%，多只产品回报超6%，显著跑赢 纯债基金。 股性主导定走势科技赛道独占鳌头 就核心指数表现来看，截至2026年1月13日，中证转债及可交换债指数（931078）报收于549.8680点， 较2026年年初的525.5226点上涨4.63%，期间最高触及557.4701点，创下阶段性新高。 量能层面同步放大，1月以来的市场成交额稳步攀升。公开数据显示，1月12日的转债市场成交额达到了 1080.95亿元，较1月5日的834.60亿元增长29.54%；1月13日虽有回调，但成交额仍维持在1023.15亿元的 高位水平，显示市场交投活跃度持续提升。 至于行业表现方面，当前的结构性行情凸显，脑机接口、AI医疗、商业航天等新兴科技领域转债表现 强势，如塞力转债因脑机接口概念，在1月5日、1月6日两个交易日内的累计涨幅达到了44%；传统行业 中，基本面改善的标 ...

Core Viewpoint - The initiative "Technology for Good" is transitioning from concept to action, with a focus on empowering disabled individuals through technology, marking a significant expansion of philanthropic efforts into the AI sector by the company [1][3]. Group 1: Philanthropic Initiatives - The company has a long-standing commitment to educational equity and child welfare, having supported various projects such as building hope primary schools in remote areas and donating nearly 280,000 yuan worth of Skechers shoes to rural children [2][6]. - The collaboration with Qiangnao Technology aims to enhance rehabilitation training and social integration for disabled individuals, leveraging Qiangnao's leadership in non-invasive brain-computer interface technology, which has achieved a valuation exceeding $1.3 billion and recently completed strategic financing of approximately 2 billion yuan [2][6]. Group 2: Future Directions - The company is evolving from being a resource supporter to a co-builder of the philanthropic ecosystem, intending to actively connect the Thinking Public Welfare platform with innovative technological forces [3][7]. - The company emphasizes that philanthropy is not just about giving but about co-creating value, aiming to create sustainable and replicable social value through the integration of investment, philanthropy, and technology [2][7].

中证报中证网讯(记者张凌之)1月15日，华银基金基金经理庞文杰在中国证券报"中证点金汇"直播间表 示，当前脑机接口的应用场景可以分为"医疗刚需"和"非医疗拓展"两大类，其中医疗领域是目前最成 熟、需求最迫切的方向，也是商业化的先行阵地。未来3-5年或将是医疗级脑机接口的商业化关键期， 而消费级应用可能以非侵入式的应用先行，预计今年就能够看到相关产品的商业化落地。未来随着技术 成熟，半侵入式和介入式的脑机接口也有望在一些高端消费场景得到应用。 ...

Core Insights - The brain-computer interface (BCI) sector has seen over a 30% increase in just a few trading days, with companies like Xiangyu Medical and Mylande doubling in value, reflecting a more than 100% rise since early 2025, indicating a rapid industrialization of a technology once confined to science fiction [1][2] - Recent clinical breakthroughs in invasive BCIs have enabled paralyzed patients to perform tasks through thought, while non-invasive technologies are entering daily life, marking a significant shift in health management from monitoring to guidance [1][6] - China is set to implement its first BCI medical device industry standards on January 1, 2026, paving the way for technology transformation and clinical application [1][5] Industry Overview - The BCI sector is emerging as a strategic battleground between the US and China, integrating neuroscience, artificial intelligence, and microelectronics, with implications for healthcare, military, and cognitive enhancement [2] - The global BCI market was valued at $1.5 billion in 2021 and is projected to grow to $3.3 billion by 2027, with a compound annual growth rate (CAGR) of approximately 17.35% [6][9] - In China, the BCI market is expected to reach 3.2 billion yuan in 2024, with an 18.81% year-on-year growth, and further growth to 3.8 billion yuan in 2025 and 4.6 billion yuan in 2026 [6] Technological Developments - Companies like Neuralink are innovating with minimally invasive surgical techniques for BCI devices, while MergeLabs focuses on non-invasive ultrasound technology [3][9] - The BCI technology landscape is diversifying, with various companies exploring both invasive and non-invasive pathways, accelerating global market expansion [9][10] - The development of flexible microelectrodes and wireless transmission modules is crucial for the future of BCI technology, with significant cost reductions expected in the coming years [12][14] Application Scenarios - BCIs are being utilized in various applications, including cognitive rehabilitation, emotional assessment, and even potential replacements for certain neurological medications, indicating a shift towards digital therapies [21][22] - The medical health sector remains the largest application area, accounting for approximately 47.62% of BCI applications, with products entering clinical pathways and regulatory approval processes [20] - Non-medical applications are also expanding, with consumer electronics and entertainment sectors beginning to adopt BCI technologies, indicating a broadening of market opportunities [21] Investment Opportunities - Companies with strong engineering capabilities and real orders are positioned to benefit from the BCI boom, as the sector approaches a critical commercialization phase [23][24] - Notable players include Micron Brain Science, which is focusing on invasive BCI technologies, and Xiangyu Medical, which is pursuing a non-invasive, full-chain self-research approach [24][25] - The market is expected to undergo significant consolidation, with companies that lack foundational technology likely to be eliminated, while those with robust product offerings and clinical pathways will thrive [26][27]

Core Insights - The A-share market has seen increased activity and emerging themes following the "opening red" in 2026, with a shift in broker research focus towards AI applications and brain-computer interfaces (BCI) [1][2] Group 1: Broker Research Trends - Broker research is increasingly focusing on high-growth industries, performance certainty, and valuation attractiveness, reflecting three major trends: a balanced investment style, a shift from speculative trading to performance realization, and a focus on domestic self-sufficiency and global competitiveness [2][7] - From January 1 to January 14, 2026, over 260 A-share companies were researched by institutions, with more than 230 receiving broker attention, highlighting a strong interest in companies like 壹网壹创, 成都先导, and 翔宇医疗 [3][4] Group 2: Key Companies and Their Focus - 壹网壹创, a leading company in the GEO concept, received attention from 27 brokers, focusing on its R&D investments and partnerships with platforms like Alibaba [4][5] - Other notable companies include 凯盛科技 and 海天瑞声, which received 22 and 21 broker inquiries respectively, with a focus on technological innovation in their respective fields [4] - Companies like 爱朋医疗, 中集集团, and 振江股份 also garnered significant broker interest, indicating a diverse range of sectors being explored [4] Group 3: Market Performance and Investment Opportunities - The AI application index and GEO index saw increases of 18.30% and 44.14% respectively from January 5 to January 15, 2026, indicating strong market interest in these sectors [8] - The global GEO market is projected to reach $24 billion by 2026 and $100 billion by 2030, with domestic expectations of reaching 11.1 billion yuan in 2026 [10] - Investment opportunities are emerging in the AI marketing sector, with a focus on companies that can leverage marketing technology and content creation [10][11] Group 4: Brain-Computer Interface (BCI) Insights - The BCI sector is expected to see significant growth, with applications in various fields such as healthcare and consumer products, driven by technological advancements and diverse application scenarios [12][13] - The global BCI market is projected to reach $7.63 billion by 2029, highlighting the potential for substantial investment opportunities in this emerging field [13]

Core Viewpoint - The article discusses the emerging interest in brain-machine interfaces (BMIs) in the capital market, particularly following Elon Musk's provocative ideas about achieving "semi-immortality" through technology [1][2][3]. Industry Overview - The BMI sector has seen a surge, with nearly 50 related companies involved in medical devices, consumer electronics, and content provision, leading to a market capitalization exceeding 1 trillion RMB within just nine trading days in 2026 [1]. - The global BMI market size grew from $1.2 billion in 2019 to nearly $2 billion in 2023, with a compound annual growth rate (CAGR) of over 13% [11]. Company Developments - Musk's Neuralink aims to create a BMI that captures consciousness through invasive methods, while domestic companies like Qiangnao Technology focus on non-invasive techniques, emphasizing safety and rehabilitation [7][10]. - Qiangnao Technology, founded in 2015, has developed the world's first non-invasive brain-controlled bionic hand and has achieved significant market penetration, producing 100,000 units at a fraction of the cost of similar international products [9][10]. Competitive Landscape - The competition between Musk's invasive approach and domestic non-invasive methods represents a broader cultural and technological divergence, with domestic firms prioritizing life preservation and rehabilitation over radical technological replacement [8][11]. - Both Neuralink and Qiangnao Technology are accelerating their efforts, with Neuralink planning large-scale production by 2026 and Qiangnao Technology preparing for an IPO after securing approximately 2 billion RMB in funding [11]. Future Goals - Qiangnao Technology aims to assist 1 million individuals with physical disabilities and improve the lives of 10 million patients suffering from various neurological conditions within the next five to ten years [12].

Market Overview - The A-share market opened lower with the Shanghai Composite Index down 0.48%, the Shenzhen Component down 0.63%, the ChiNext Index down 0.93%, and the Sci-Tech Innovation Board down 0.94% [2][3] - The Hang Seng Index opened down 0.1%, and the Hang Seng Tech Index fell by 0.55% [6][7] Sector Performance - AI application stocks, CRO, commercial aerospace, brain-computer interface, nuclear fusion, and robotics concepts saw significant declines [1][3] - Energy metals, cybersecurity, and cross-border payment concept stocks remained active [3] Notable Stocks - Sunflower (向日葵) opened at a limit down due to an investigation by the China Securities Regulatory Commission for suspected information disclosure violations, leading to the termination of its asset restructuring [3][4] - Tianpu Co. (天普股份) approached a limit down after receiving an inquiry letter from the Shanghai Stock Exchange regarding its main business and executive qualifications [4][5] - Ctrip Group (携程集团) fell nearly 15% following an investigation by the market regulatory authority [6][7]

Core Viewpoint - The A-share market is experiencing extreme enthusiasm, prompting regulatory measures to cool down the market, indicating a shift towards a "slow bull" market rather than a "crazy bull" market, emphasizing the need for investors to focus on fundamentals rather than emotions [5][6]. Market Sentiment and Regulatory Response - On January 14, the exchange announced an increase in the minimum margin ratio for financing from 80% to 100%, leading to an immediate market downturn [5]. - The regulatory stance is clear: the market can rise, but it should not be driven solely by emotions, and investors must return to fundamentals [6]. Investment Opportunities and Risks - The focus should be on identifying key sectors that are likely to perform well while avoiding those that may pose risks [7][8]. - The analysis will cover 13 high-interest sectors to provide insights on potential investment opportunities [9]. AI Computing Power - The rise of AI infrastructure is supported by increased investments from cloud vendors, with companies like "易中天" (New Yizhong, Zhongji Xuchuang, Tianfu Communication) showing significant stock price increases [11]. - However, the current high valuations may be unsustainable, and without new positive developments, there is a risk of a bubble burst in this sector [11]. Space Computing Industry - The space computing industry is expected to emerge as a significant market, with technologies deploying data centers in space to address ground-based limitations [13][15]. - China's advancements in space computing are supported by government initiatives, with plans for a comprehensive deployment strategy by 2025 [17][18]. Humanoid Robots - The humanoid robot sector is anticipated to see differentiation by 2026, with industrial applications being the primary focus, while household robots remain underdeveloped [20][22]. - Companies like 优必选 (UBTECH) are ramping up production, with expectations of significant output increases in the coming years [22][23]. Semiconductor Equipment - Domestic wafer fabs are planning expansions to meet AI chip demand and enhance production capacity, which will benefit semiconductor equipment suppliers [25][26]. Controlled Nuclear Fusion - The commercialization of controlled nuclear fusion is accelerating, with multiple technological pathways being explored [28][30]. - China is making significant strides in fusion energy, with projects like EAST and BEST expected to lead to practical applications by 2027 [32][33]. Commercial Aerospace - The commercial aerospace sector is experiencing a surge, driven by fears of missing out on investment opportunities, although there are concerns about the sustainability of this growth [41][42]. - China's satellite deployment is rapidly increasing, positioning the country as a major player in the global space race [44]. Photovoltaics - The photovoltaic sector is expected to reach a turning point in 2026, driven by supply-side adjustments and improved fundamentals [47][51]. - The cancellation of export tax rebates is likely to increase costs for exporters, benefiting larger firms with economies of scale [51][52]. Consumer Sector - The consumer sector is seen as a safe haven during market volatility, with specific focus areas including media, service consumption, and premium goods like liquor [66][70]. - The overall consumer demand is expected to recover gradually, but structural changes may lead to a lack of strong support for broad-based growth [67]. Banking Sector - The banking sector has shown resilience despite fundamental pressures, with attractive dividend yields drawing in long-term investors [72][73]. - However, the sector is unlikely to lead the market due to its lower growth potential compared to technology and growth stocks [74]. Insurance Sector - The insurance sector has outperformed banks, benefiting from stock market recovery and expected growth in both asset and liability sides [76]. - The aging population is likely to increase the importance of insurance companies in key areas like healthcare and retirement [76]. Brokerage Firms - Brokerage firms have seen strong earnings growth but face challenges in maintaining investor interest due to perceived volatility and lack of long-term growth [77].

Group 1 - The construction of a "super factory" by Brain Tiger Technology in Jiangxi marks a significant transition from laboratory research to large-scale production in the brain-computer interface (BCI) sector, aiming for stable supply of tens of thousands of units [1][6] - The factory will produce China's first and the world's second fully implanted, fully wireless, and fully functional BCI system, highlighting the growing market potential across healthcare, consumer electronics, and military applications [1][6] - Global developments include Neuralink's announcement to start large-scale production of BCI devices by 2026, indicating a shift from clinical validation to industrialization [1][6] Group 2 - The Chinese government is actively promoting the BCI industry, with a policy document aiming for breakthroughs in key technologies by 2027 and a robust industry system by 2030 [2][7] - The "14th Five-Year Plan" identifies BCI as a future industry requiring strategic development, with various regions setting clear goals for BCI technology and product applications [2][7] - Successful surgeries have been performed on high-level paraplegics using BCI technology, enabling patients to control devices and participate in rehabilitation and employment activities [2][7] Group 3 - The BCI sector has attracted significant investment, with the A-share market showing a cumulative increase of over 20% since 2026, and several stocks rising more than 50% [3][8] - As of January 13, 2023, the financing balance for 26 BCI-related stocks reached nearly 25.5 billion yuan, a 15% increase from the previous year, with many stocks seeing substantial increases in their financing [3][8] - Notable companies include Meihua Medical, with a financing balance of 470 million yuan and a 255% increase, and Innovation Medical, with a balance of 744 million yuan and a 105% increase [3][8][9]

Group 1 - The core point of the article highlights the significant advancements in the brain-computer interface (BCI) industry, particularly with the construction of Brain Tiger Technology's "super factory" in Jiangxi, which marks a transition from laboratory research to large-scale production of BCI systems [3] - The factory aims to produce the first domestically developed and the world's second fully implanted, wireless, and fully functional BCI system, targeting stable supply of tens of thousands of units [3] - The BCI technology shows immense potential across various sectors, including healthcare, consumer electronics, and military aerospace, with significant developments occurring globally [3] Group 2 - The Chinese government is actively promoting the BCI industry, with a policy document issued in July 2025 outlining goals for technological breakthroughs and the establishment of a robust industry framework by 2030 [4] - The market for BCIs is projected to grow significantly, with global market size expected to reach approximately $2.62 billion in 2024 and $12.4 billion by 2034, while China's market is anticipated to grow from 3.2 billion yuan in 2024 to 5.58 billion yuan by 2027, reflecting a compound annual growth rate of about 20% [4] Group 3 - The BCI sector has attracted substantial investment, with the A-share market seeing a cumulative increase of over 20% in the BCI theme index since 2026, and several stocks experiencing gains exceeding 50% [5] - As of January 13, 2023, 19 out of 26 BCI concept stocks were eligible for margin trading, with a total financing balance of nearly 25.5 billion yuan, an increase of over 15% compared to the end of the previous year [5] - Notable companies such as Meihua Medical and Innovation Medical have seen significant increases in their financing balances, indicating strong investor interest and strategic partnerships in the BCI field [5][6]